Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y₁₂ Inhibitors is Not Feasible or Desirable, in Spain

Table 2 Distribution (in Percentage) of the Use of GPIs and Oral P2Y₁₂ Inhibitors without and with Cangrelor in the Hospital Formulary in the PCI Population in Spain

Table 3 Efficacy and Safety Outcome Rates of P2Y₁₂ Inhibitors in the PCI Population in Spain

Figure 1 Three years distribution of the total, primary PCI and PCI population in whom antiplatelet therapy with oral P2Y₁₂ inhibitors is not feasible or desirable, in Spain.

Figure 1 Three years distribution of the total, primary PCI and PCI population in whom antiplatelet therapy with oral P2Y12 inhibitors is not feasible or desirable, in Spain.

Table 4 Assumptions Considered in the Budget Impact Model (Base Case)

Table 5 Budget Impact Results for Cangrelor Amongst PCI Patients in Whom Antiplatelet Therapy with Oral P2Y₁₂ Inhibitors is Not Feasible or Desirable in Spain (Three-Year Time Horizon)

Table 6 Distribution of Clinical (Ischemic and Bleeding) Events Amongst PCI in Whom Antiplatelet Therapy with Oral P2Y₁₂ Inhibitors is Not Feasible or Desirable in the Scenarios without and with Cangrelor in the Hospital Formulary in Spain (Three-Year Time Horizon)

Figure 2 Pharmacological and clinical event costs before and after introducing cangrelor into the hospital formulary in Spain for managing PCI patients in whom oral P2Y₁₂ inhibitors are not feasible or desirable (three-year time horizon).

Figure 3 Tornado diagram: influence of key inputs on the budget impact of cangrelor for managing PCI patients in whom oral P2Y₁₂ inhibitors are not feasible or desirable, in Spain.

Figure 3 Tornado diagram: influence of key inputs on the budget impact of cangrelor for managing PCI patients in whom oral P2Y12 inhibitors are not feasible or desirable, in Spain.

Serrador, Frutos AM, Jiménez-Quevedo P, Pérez de Prado A, Pan Álvarez-ossorio M. Spanish Cardiac Catheterization and Coronary Intervention Registry. 26th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2016). Rev Española Cardiol (English Ed. 2017;70(12):1110–1120. doi:10.1016/j.rec.2017.10.017

Cid Álvarez AB, Rodríguez, Leor O, Moreno R, Pérez de Prado A. Spanish Cardiac Catheterization and Coronary Intervention Registry. 27th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2017). Rev Española Cardiol (English Ed. 2018;71(12):1036–1046. doi:10.1016/j.rec.2018.09.009

Sociedad Española de Cardiología. Registro Nacional de Actividad de Cardiología Intervencionista - Sección Hemodinámica. Registro de Actividad; 2017. https://www.hemodinamica.com/cientifico/registro-de-actividad/. Accessed October 3, 2019.

Kataja A, Harjola V-P. Cardiogenic shock: current epidemiology and management. Contin Cardiol Educ. 2017;3(3):121–124. doi:10.1002/cce2.62

Anderson ML, Peterson ED, Peng SA, et al. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification a report from NCDR. Circ Cardiovasc Qual Outcomes. 2013;6(6):708–715. doi:10.1161/CIRCOUTCOMES.113.000262

Expert Consensus. Ferrer Galenica. 2019.

Talegon Albariño I, García García J, Gross Kasztanovits E;, Martín Conde JA, Crespo C, Rodríguez Barrios JM. Análisis del Impacto Presupuestario de los nuevos antiagregantes plaquetarios prasugrel (Efient) y ticagrelor (Brilique) frente a la terapia estándar con clopidogrel en el tratamiento de pacientes con Síndrome Coronario Agudo sometidos a Intervención Co. 2018;13(5):882–893.

Hamon M, Nienaber CA, Galli S, et al. Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. Int J Cardiol. 2014;173(2):290–294. doi:10.1016/j.ijcard.2014.03.003